Two-years results after femtosecond laser-assisted circular keratotomy as a treatment for keratoconus stage I-II: comparison between two different age groups

Session Details

Session Title: Cornea
Session Date/Time: Sunday 28/02/2016 | 08:30-11:00
Paper Time: 09:12
Venue: MC2 Room
First Author: : E.Taylor GERMANY
Co Author(s): :    D. Breyer   J. Krumeich   H. Kaymak   K. Klabe   P. Hagen  

Abstract Details

Purpose:

Circular keratotomy (CKT) represents an effective treatment of the progression of keratoconus. Recently, we refined the CKT by replacing the trephine cut technique by a Femtosecond laser-induced intracorneal cut (Femto-CKT), rendering sutures unnecessary.

Setting:

All Femto-CKT (Femto LDV, Ziemer) treatments and follow-ups were performed at the Breyer-Kaymak-Klabe Eyesurgery in Duesseldorf, Germany, and the Gemeinschaftspraxis & Klinik Dr. med. Joerg H. & Bert Krumeich in Bochum Germany.

Methods:

The aim of this retrospective quality management investigation is to address the question, whether patient age has a significant influence on the prospect of success of Femto-CKT in treating keratoconus of stage I and II. So far, the results of 40 eyes are evaluated over up to 24 months after Femto-CKT. Visual acuity at far (CDVA) and manifest refraction were measured. Corneal radii were assessed with Scheimpflug tomography (Pentacam). Furthermore, optical coherence tomography of the anterior segment was performed with Visante OCT. We compared the results of patients younger than 35 years with those that were older than 35 years.

Results:

In all eyes, no signs of a progressing keratoconus were found. Corneal radii and refractive values remained stable within the two-year period of observation. CDVA was <0.00LogMAR two year after surgery and improved compared to its preoperative value. No significant differences were found between the two age groups.

Conclusions:

So far, our results indicate that Femto-CKT is an efficient way to stop the progression of keratoconus of stage I and II. The success of the treatment appears to be independent of the patient age.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, One or more of the authors travel has been funded, fully or partially, by a competing company, One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One or more of the authors receives consulting fees, retainer, or contract payments from a competing company